US2020179317A1PendingUtilityA1

Combination therapy for head and neck cancer

55
Assignee: UNIV CORNELLPriority: Mar 10, 2014Filed: Nov 20, 2019Published: Jun 11, 2020
Est. expiryMar 10, 2034(~7.6 yrs left)· nominal 20-yr term from priority
Inventors:Lorraine J GudasXiao-Han TangKwame Osei-SarfoAlison Urvalek
A61K 31/192A61K 38/177A61K 31/203A61K 31/44A61K 45/06A61P 35/00A61K 9/0019A61K 9/0053
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to pharmaceutical composition and methods of using RXR agonist and/or RAR agonist for the treatment or prevention of head and neck cancer.

Claims

exact text as granted — not AI-modified
1 .- 57 . (canceled) 
     
     
         58 . A method for treating a squamous cell carcinoma in a subject, the method comprising: administering to said subject a Retinoid X Receptor (RXR) agonist in combination with a Retinoic Acid Receptor (RAR) agonist, thereby treating said squamous cell carcinoma in said subject. 
     
     
         59 . The method of  claim 58 , wherein said squamous cell carcinoma is head and neck squamous cell carcinoma (HNSCC). 
     
     
         60 . The method of  claim 58 , wherein said squamous cell carcinoma is oral cancer. 
     
     
         61 . The method of  claim 58 , wherein said squamous cell carcinoma is oral cavity squamous cell carcinoma or locally advanced malignant squamous cell carcinoma. 
     
     
         62 . The method of  claim 58 , wherein said administration of said RXR agonist in combination with said RAR agonist reduces the number of cancer stem cells in oral cavity. 
     
     
         63 . The method of  claim 58 , wherein said administration is an oral administration. 
     
     
         64 . The method of  claim 63 , wherein said administration is by oral rinse. 
     
     
         65 . The method of  claim 58 , wherein said administration is intravenous or subcutaneous administration. 
     
     
         66 . The method of  claim 58 , wherein said administration is a co-administration of said RXR agonist and said RAR agonist. 
     
     
         67 . The method of  claim 58 , wherein said administration comprises an independent administration of RXR agonist and said RAR agonist. 
     
     
         68 . The method of  claim 58 , wherein said squamous cell carcinoma is caused by tobacco, cigar smoking, alcohol, virus, carcinogen, irradiation, or a combination thereof. 
     
     
         69 . A composition comprising a Retinoid X Receptor (RXR) agonist and a Retinoic Acid Receptor (RAR) agonist, both present in an amount effective to treat a squamous cell carcinoma in a subject. 
     
     
         70 . The composition of  claim 69 , wherein said squamous cell carcinoma is head and neck squamous cell carcinoma (HNSCC). 
     
     
         71 . The composition of  claim 69 , wherein said squamous cell carcinoma is oral cancer. 
     
     
         72 . The composition of  claim 69 , wherein said squamous cell carcinoma is oral cavity squamous cell carcinoma or locally advanced malignant squamous cell carcinoma. 
     
     
         73 . The composition of  claim 69 , wherein said composition is effective to reduce the number of cancer stem cells in oral cavity. 
     
     
         74 . The composition of  claim 69 , wherein said composition is suitable for oral administration. 
     
     
         75 . The composition of  claim 74 , wherein said administration is by oral rinse. 
     
     
         76 . The composition of  claim 69 , wherein said composition is suitable for intravenous or subcutaneous administration. 
     
     
         77 . The composition of  claim 69 , wherein said squamous cell carcinoma is caused by tobacco, cigar smoking, alcohol, virus, carcinogen, irradiation, or a combination thereof.

Join the waitlist — get patent alerts

Track US2020179317A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.